Abstract 1582P
Background
Emerging evidence suggests that the defective homologous recombination repair (HRR) of DNA double-strand breaks (DSBs) in human trophoblast cells may induce spontaneous miscarriage (SM), as indicated by lower levels of BRCA1/RAD51 and higher levels of DSBs in villous tissue samples of recurrent SM. Furthermore, cancer therapies can induce DNA damage not only in cancer cells but also in healthy cells, including oocytes. Oocytes have the capacity to repair DSBs during meiosis. DNA damage in oocytes induces meiotic errors, leading to abnormalities and increased susceptibility to SM.
Methods
This was a real-world, hospital-based, study, including EOC patients undergoing BRCA1/2 tumor (t), germline (g), and genomic instability testing between May 2015 and May 2024. In the current analysis we investigate cumulative incidence of pregnancy and miscarriage according to BRCA1/2 mutational status (presence/absence of t/g (likely)pathogenic variants, PVs), and HRD status (HRD positive/negative) assessed by myChoiceCDx/SOPHiA DDM™ assays. Patients carriers of PVs in HR no-BRCA1/2 genes were excluded.
Results
Six hundred and thirty-five (635) EOC patients were included in the analysis: 130 were carriers of gPVs in BRCA1/2 genes (20.5%): 86 in BRCA1 (66.1%) and 44 in BRCA2 (33.9%); while 33 showed tPVs (5.2%). Of the 135 samples analyzed by the HRD genomic instability test, 51 (37.8%) were identified as HRD-positive, and 69 (51.1%) as HRD-negative. When the cumulative incidence of pregnancy between the groups was compared, the difference was not significant. Notably, HRD-positive EOC patients showed a statistically significant increase in miscarriage, compared to patients in the HRD negative subgroup (31.1% vs 12.1%, respectively; p=0.02).
Conclusions
Our data suggested that pregnancy in EOC patients with HRD positive tumors is associated with increased incidence of miscarriage. Prospective validation of these findings is required. Meanwhile, oncofertility counseling, and a more in-depth assessment of risk factors, could be proposed to optimize abortion risk-management and improve fetal and obstetric outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10